SM
JSPR icon

Scoggin Management’s Jasper Therapeutics JSPR Stock Holding History

Scoggin Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50,805
Closed -$356K – 68
2023
Q3 		$356K Buy
+50,805
New +$620K 0.15% 55

Other funds holding JSPR

ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Scoggin Management's JSPR Position: Q4 2023 in Review

Scoggin Management sold out of Jasper Therapeutics (JSPR) in Q4 2023, closing a stake of 50,805 shares — an estimated $356K sold.

Scoggin Management first reported a position in JSPR in Q3 2023 and held it in 1 quarter. The position peaked at $356K in Q3 2023. 41 funds tracked by Wall St. Rank hold JSPR as of Q4 2023.

  • Scoggin Management reported no remaining Jasper Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Scoggin Management sold 50,805 Jasper Therapeutics shares in Q4 2023, an estimated $356K.
  • Scoggin Management first reported a position in Jasper Therapeutics in Q3 2023 and held it in 1 quarter.
  • Scoggin Management's Jasper Therapeutics position peaked at $356K in Q3 2023.
  • 41 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2023.

Based on Scoggin Management's 13F filing for Q4 2023, filed 14 Feb 2024.